CLINICAL_TRIALS
trial_result
· 2017-07-27
Clinical Trial Update: RDEA3170 and Febuxostat Combination Study in Gout Subjects [Phase 2]
Summary
Phase 2 study evaluating the combination of RDEA3170 and febuxostat in gout subjects has completed. Results have been posted (July 27, 2017).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 2 | Status: COMPLETED | Results posted: 2017-07-27